Myeloprotection effect of trilaciclib in lung cancer patients undergoing chemotherapy: a real-world retrospective study.

J Thorac Dis · 2026 · PMC13358833 · PMID 42444864

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

did not reach statistical significanceP=0.09so close (0.05 < p ≤ 0.1)

In the unweighted analysis, the incidence of any-grade myelosuppression was numerically higher in the non-trilaciclib group but did not reach statistical significance (OR =2.35, 95% CI: 0.86–6.39, P=0.09).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.